The PALMD (Palmdelphin) antibody targets a protein belonging to the synaptic vesicle-associated membrane protein family, which shares homology with synaptotagmins. PALMD encodes a cytosolic protein predominantly expressed in cardiac and neuronal tissues, characterized by two C2 domains that mediate calcium-dependent membrane interactions. It plays a role in regulating intracellular trafficking, exocytosis, and calcium signaling, potentially influencing synaptic transmission and vesicle dynamics. Studies suggest PALMD interacts with proteins involved in membrane fusion, such as syntaxins, and may modulate pathways linked to cardiovascular function and neurodegeneration. Dysregulation of PALMD has been implicated in pathologies like dilated cardiomyopathy and Alzheimer’s disease. Antibodies against PALMD are widely used in research to investigate its expression, localization, and mechanistic roles via techniques like Western blot, immunohistochemistry, and immunofluorescence. Recent interest in PALMD also extends to cancer biology, where its aberrant expression may correlate with tumor progression. These tools help unravel its physiological and pathological contributions, aiding therapeutic target discovery.